Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829903 | 0.91 | DHPS (0.34) | MAPK1S1PR1LMNAHTTHSD17B10 | |
| SCHEMBL1832226 | 0.89 | MAPK1 (0.38) | MAPK1S1PR1LMNAHTTHSD17B10 | |
| SCHEMBL1828719 | 0.88 | S1PR1 (0.38) | MAPK1S1PR1HPGD | |
| SCHEMBL1829061 | 0.88 | DRD4 (0.31) | MAPK1S1PR1LMNAHTTHSD17B10 | |
| SCHEMBL1829171 | 0.86 | ALOX5 (0.36) | MAPK1S1PR1LMNAHTTHSD17B10 | |
| SCHEMBL1828317 | 0.86 | S1PR1 (0.39) | MAPK1S1PR1LMNAHTTHSD17B10 | |
| SCHEMBL1829092 | 0.86 | S1PR1 (0.46) | MAPK1S1PR1HTTKDM4EALDH1A1 | |
| SCHEMBL1829893 | 0.85 | HRH3 (0.37) | MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL1829491 | 0.85 | S1PR1 (0.39) | MAPK1S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL1828664 | 0.84 | KMT2A (0.34) | MAPK1S1PR1LMNAHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| EP-2318415-B1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI SA (FR) | 2013-02-20 | — | — | EP | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2318415-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006704-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | EDNRA, OXGR1, EDF1 | MAPK1 742/4885S1PR1 49/4885LMNA 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.